2017 ACVIM Forum Research Abstract Program

Forty-six cats were recruited (glargine=24, PZIR=22). No significant difference in MBG, fructosamine, BID insulin dose, DIA-QoL-pet score, or DCS was identified between groups at any time point. Eight glargine-treated cats (33.3%) and five PZIR-treated cats (23%) achieved remission (P = 0.42). Baseline bodyweight >5.2 kg (hazard ratio (HR) 2.7; 95% confidence interval (CI) 0.9-8.3; P = 0.07), baseline feline body mass index ≥25% (HR 3.3; 95% CI 1.1-10.0; P = 0.04) and ≥2% weight loss at the 1-month time point (HR 12.9; 95% CI 3.5-47.4; P = 0.0002) were identified as possibly associated with remission during univariate analysis (criterion: P < 0.1). Multivariable analysis revealed a minimum of 2% weight loss at the 1-month time point to be the only significant predictor of remission (HR 13.5; 95% CI 2.9-62.5; P = 0.0009).